Analysts predict that Agios Pharmaceuticals (NASDAQ:AGIO) will post $13.59 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Agios Pharmaceuticals’ earnings. The lowest sales estimate is $10.60 million and the highest is $17.00 million. Agios Pharmaceuticals posted sales of $10.51 million in the same quarter last year, which indicates a positive year-over-year growth rate of 29.3%. The business is expected to report its next earnings results before the market opens on Thursday, May 3rd.
On average, analysts expect that Agios Pharmaceuticals will report full-year sales of $111.39 million for the current fiscal year, with estimates ranging from $58.30 million to $215.80 million. For the next year, analysts forecast that the business will report sales of $311.22 million per share, with estimates ranging from $85.66 million to $734.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The business had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $12.65 million. During the same period last year, the company posted ($1.34) earnings per share. The firm’s revenue for the quarter was down 56.7% on a year-over-year basis.
In other news, CEO David P. Schenkein sold 53,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the transaction, the chief executive officer now owns 53,000 shares of the company’s stock, valued at $3,877,480. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Corp /De/ Celgene purchased 851,154 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, January 23rd. The shares were bought at an average cost of $67.00 per share, for a total transaction of $57,027,318.00. Following the transaction, the insider now directly owns 1,374,599 shares of the company’s stock, valued at approximately $92,098,133. The disclosure for this purchase can be found here. Insiders have sold 210,880 shares of company stock worth $16,368,948 in the last ninety days. Corporate insiders own 5.43% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Agios Pharmaceuticals by 41.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 762 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $160,000. Bank of Montreal Can lifted its position in shares of Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 1,520 shares during the last quarter. Macquarie Group Ltd. bought a new position in shares of Agios Pharmaceuticals during the third quarter worth about $245,000. Finally, Xact Kapitalforvaltning AB bought a new position in shares of Agios Pharmaceuticals during the fourth quarter worth about $259,000. 82.41% of the stock is currently owned by institutional investors and hedge funds.
Shares of Agios Pharmaceuticals stock opened at $87.33 on Friday. The firm has a market cap of $4,834.36, a P/E ratio of -12.94 and a beta of 1.98. Agios Pharmaceuticals has a twelve month low of $45.11 and a twelve month high of $89.33.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.